BIO-RAD ABD SEROTEC LTD

• ⚠

  Confirmation statement overdue

  Due 2026-05-03.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -6.7%

  £10,424,591 → £9,725,099

• Cash

  +17.8%

  £578,565 → £681,325

• Net assets

  -1.5%

  £28,537,460 → £28,095,761

• Employees

  -11.3%

  80 → 71

• Operating profit

  +0.3%

  -£1,544,713 → -£1,540,315

• Profit before tax

  -2.5%

  -£750,915 → -£769,707

• Wages

  -18.8%

  £4,360,644 → £3,539,645

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. BIO-RAD ABD SEROTEC LTD 2013-05-17 → present
2. MORPHOSYS UK LIMITED 2007-01-02 → 2013-05-17
3. SEROTEC LIMITED 1982-06-01 → 2007-01-02
4. SEVENDALE LIMITED 1981-12-16 → 1982-06-01

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis, which the directors consider to be appropriate for the following reasons. The company's activities are to manufacture and distribute antibodies principally to customers within the group and to a small number of third-party customers. The activities of the company are considered by the directors to be integral to the operations of the group as the group could not readily replace the company's manufacturing capability in the short to medium term. The ability of the company to continue as a going concern is therefore dependent on the ability of the Bio-Rad Laboratories Inc. group to continue as a going concern and Bio-Rad Laboratories Inc. group entities paying for intra-group services and products in accordance with the transfer pricing policies in place, during the forecast period. There are no known concerns with the group's ability to continue as a going concern. The directors have prepared cash flow forecasts for a period of 12 months from the date of approval of these financial statements which indicate that, taking account of reasonably possible downsides in revenue, margins, the anticipated impact of the current economy on the operations and its financial resources, the company will have sufficient funds to meet its liabilities as they fall due for that period. The company continues to use the group cash pooling arrangement. At 31 December 2024 the company was a net contributor to the cash pool and is expected to remain a net contributor throughout the going concern assessment period, even taking account of reasonably possible downsides. The nature of the agreement and structure of the cash pooling arrangement means that the company will have immediate unrestricted access to both the cash it has deposited and any additional cash it requires to continue its operations during the forecast period, in the unlikely event that this should this be necessary. Consequently, the directors are confident that the company will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.”

Group structure

1. BIO-RAD ABD SEROTEC LTD · parent
   1. Bio-Rad AbD Serotec GmbH 1% · Germany · sale and distribution of antibodies

Significant events

• “In 2024, the business experienced a 7% decline in revenue, primarily driven by changes in the product mix. Income from recharges decreased by £210,428 to £1,499,644, and administrative expenses decreased by £871,655, mainly due to a reduction in headcount. The company guarantees £120,000 to HM Revenue & Customs for deferred duty payments.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.